ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside
02 nov. 2023 08h00 HE
|
Artidis AG
Houston, Texas, and Basel, Switzerland, November 2nd, 2023 – As Breast Cancer Awareness Month concludes, ARTIDIS announces the launch of its global multicenter clinical trial, ARTIDIS Nanomechanical...
ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors
13 févr. 2023 07h15 HE
|
Artidis AG
ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors Basel, Switzerland, February 13, 2023 – ARTIDIS AG, a clinical stage medical technology company on a mission to shift...
MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment
03 oct. 2022 09h05 HE
|
ARTIDIS AG
HOUSTON and BASEL, Switzerland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- ARTIDIS AG, the developer of the first nanomechanical technology platform for tissue analytics, and The University of Texas MD...